<DOC> 
<DOCNO>1080313_business_story_9013974.utf8</DOCNO> 
<TEXT> 
         
The Telegraph - Calcutta (Kolkata) | Business | Suven Life in pact with Lilly
                                                                                                               Suven Life in pact with Lilly
          OUR SPECIAL CORRESPONDENT                          HEALTH CHECK                                  
	Mumbai, March 12: Suven Life Sciences has entered into a second agreement with US-based Eli Lilly to collaborate on the pre-clinical research of molecules used in the treatment of central nervous system (CNS) disorders.        
	According to the agreement, Suven will be responsible for identification and selection of clinical candidates.        
	Suven will receive research funding as well as payments of up to $23 million per candidate for potential discovery and development.         
	It will also receive royalties on net sales of any product that may be successfully commercialised from the collaboration.         
	We are very pleased and excited that Lilly continues to collaborate with us in the CNS arena, thus showing confidence in Suvens drug discovery capabilities, Ramakrishna Nirogi, vice-president (drug discovery) of Suven Life Sciences said.        
	Venkat Jasti, CEO of Suven Life Sciences, said the collaboration would leverage the Indian firms experience in small molecule drug discovery with Lillys expertise and leadership in CNS.        
	Earlier in 2006, Suven had signed a similar agreement with Lilly for CNS disorders.        
	Suven Life Sciences is engaged in the design, manufacture and supply of drug intermediates and fine chemicals. Its other areas include contract research and manufacturing services and drug discovery development support services.         
	The Hyderabad-based company reported revenues of Rs 87.88 crore for the nine months ended December 2007 compared with Rs 85.85 crore for the corresponding period of the previous year.         
	After the announcement of the pact with Lilly, the Suven scrip rose 6.6 per cent to close at Rs 37.40 on the BSE.                                                                                                                                        
</TEXT> 
</DOC>